Marks Gilbert Lynn has filed 15 insider transactions across 1 company since June 2023.
Most recent transaction: a grant/award of 10665 shares of AN2 Therapeutics, Inc. ($ANTX) on March 19, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Stock Option (right to buy) | 10665 | $0.00 | 10,665.0000 | 30,276,230 | 9999.99% | 0.04% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | D | Stock Option (right to buy) | 23742 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.08% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Stock Option (right to buy) | 23742 | $0.00 | 23,742.0000 | 30,276,230 | 9999.99% | 0.08% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | D | Stock Option (right to buy) | 10362 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.03% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Stock Option (right to buy) | 10362 | $0.00 | 10,362.0000 | 30,276,230 | 9999.99% | 0.03% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | D | Stock Option (right to buy) | 10665 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.04% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Stock Option (Right to Buy) | 20400 | $0.00 | 20,400.0000 | 30,276,230 | 9999.99% | 0.07% |
| Jan. 12, 2026 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Common Stock | 11560 | $0.00 | 75,309.0000 | 30,276,230 | 18.13% | 0.04% |
| Oct. 10, 2025 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Common Stock | 10367 | $0.00 | 63,749.0000 | 30,276,230 | 19.42% | 0.03% |
| July 10, 2025 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Common Stock | 11875 | $0.00 | 53,382.0000 | 29,828,227 | 28.61% | 0.04% |
| May 22, 2025 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Stock Option (Right to Buy) | 19111 | $0.00 | 19,111.0000 | 29,828,227 | 9999.99% | 0.06% |
| April 10, 2025 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Common Stock | 9705 | $0.00 | 41,507.0000 | 29,828,227 | 30.52% | 0.03% |
| Dec. 19, 2024 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Common Stock | 8972 | $0.00 | 31,802.0000 | 29,841,169 | 39.30% | 0.03% |
| June 19, 2024 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Not found | A | Stock Option (Right to Buy) | 64503 | $0.00 | 64,503.0000 | 23,600,107 | 9999.99% | 0.27% |
| June 7, 2023 | AN2 Therapeutics, Inc. | $ANTX | Marks Gilbert Lynn | Director | A | Stock Option (right to buy) | 23742 | $0.00 | 23,742.0000 | 0 | 9999.99% | 0.00% |